• Sonuç bulunamadı

The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction

N/A
N/A
Protected

Academic year: 2021

Share "The impact of discontinuation of sacubitril–valsartan and shifting to angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in patients with heart failure with reduced ejection fraction"

Copied!
7
0
0

Yükleniyor.... (view fulltext now)

Tam metin

Referanslar

Benzer Belgeler

However, the authors measured a healthy human concentration of 16.91 (0–81) pg/mL in Figure 1a, which we consider as an important problem as to how the kit measured levels below

IL- 10 inhibited infiltration of inflammatory cells and expression of pro-inflammatory cytokines in the myocardium, improved myocardial function, and protected from adverse

We believe that exacerbation of cardiac failure and further im- paired exercise capacity in patients living at intermediate high altitudes may be attributed to that

In the present study, the prognostic significance of the BDNF values was investigated in patients with severe left ventricular systolic dysfunction (LVEF ≤35%) of mildly

In the following analysis of patients with sinus rhythm, beta blockers showed great positive effects on patients with heart rate <70 bpm (p=0.046), as for the quality of life

In our study, the concentration of IL-33 was lower in patients with HF than in healthy subjects; however, patients with stable HF were charac- terized by lower IL-33

In this study, we investigated the relationship between the New York Heart Association (NYHA) class, duration, and number of hospitalizations in the previous year and

In the Acute and Chronic Heart Failure Diagnosis and Treatment Guidelines published by the ESC in 2012, ARBs are recommended as class 1, evidence level A for HFrEF patients not